Human antipneumococcal antibodies from non-human animals

Abstract

The invention described herein provides human antibodies produced in non-human animals that specifically bind to Streptococcus pneumoniae capsular polysaccharide (PPS-3). The invention further provides methods for making the antibodies in a non-human animal and for expressing the antibodies in cells including hybridomas and recombinant host cell systems. Kits and pharmaceutical compositions comprising the antibodies are also provided in addition to methods of treating, inhibitng or preventing S. pneumoniae infection or conditions or disorders caused by such infection by administering to a patient the pharmaceutical compositions described herein.

1 - 3 . (canceled)  
     
     
         4 . A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 1;    (b) the amino acid sequence of residues 31 to 104, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 1; and    (c) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequence set forth in SEQ ID NO: 1.    
     
     
         5 - 10 . (canceled)  
     
     
         11 . A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 3;    (b) the amino acid sequence of residues 31 to 108, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 3; and    (c) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequence set forth in SEQ ID NO: 3.    
     
     
         12 - 17 . (canceled)  
     
     
         18 . A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 5;    (b) the amino acid sequence of residues 31 to 104, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 5; and    (c) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequence set forth in SEQ ID NO: 5.    
     
     
         19 - 24 . (canceled)  
     
     
         25 . A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 7;    (b) the amino acid sequence of residues 31 to 105, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 7; and    (c) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequence set forth in SEQ ID NO: 7.    
     
     
         26 - 31 . (canceled)  
     
     
         32 . A host cell transformed with a nucleic acid molecule according to any one of claims  4 ,  11 ,  18  or  25 .  
     
     
         33 . A method for producing an antibody or an antigen binding fragment thereof that specifically binds  S. pneumoniae  PPS-3, comprising the step of culturing a host cell according to  claim 32 .  
     
     
         34 - 37 . (canceled)  
     
     
         38 . A method for preventing or reducing the severity of conditions or disorders caused by  S. pneumoniae  serotype 3 infection in a subject comprising the step of administering an effective amount of the antibody or antigen-binding fragment thereof, wherein said antibody or fragment comprises a heavy chain amino acid sequence comprising an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 1;    (b) the amino acid sequence of residues 31 to 104, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 1;    (c) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequence set forth in SEQ ID NO: 1;    (d) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 3;    (e) the amino acid sequence of residues 31 to 108, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 3; and    (f) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequence set forth in SEQ ID NO: 3.    (g) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 5;    (h) the amino acid sequence of residues 31 to 104, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 5; and    (i) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequence set forth in SEQ ID NO: 5.    (j) the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 8;    (k) the amino acid sequence of residues 24 to 97, inclusive, of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 8; and    (l) the CDR1, CDR2 and CDR3 amino acid sequences encoded by the DNA sequence set forth in SEQ ID NO: 8.    
     
     
         39 - 43 . (canceled)  
     
     
         44 . The method according to claims  38 , wherein the anti- S. pneumoniae  PPS-3 antibody or antigen-binding fragment thereof is administered in conjunction with the administration of another therapeutic agent.  
     
     
         45 - 47 . (canceled)